ATE537829T1 - Therapeutische verwendung von verbindungen mit kombinierter sert-, 5-ht3 und 5-ht1a-aktivität - Google Patents

Therapeutische verwendung von verbindungen mit kombinierter sert-, 5-ht3 und 5-ht1a-aktivität

Info

Publication number: ATE537829T1
Authority: AT; Austria
Prior art keywords: compounds; therapeutic use; ht1a activity; sert; combined
Prior art date: 2007-11-13

Application number

AT08850935T

Other languages

English (en)

Inventor

Nicholas Moore

Marianne Dragheim

Aneil Batra

Jin Chon

Original Assignee

Lundbeck & Co As H

Takeda Pharmaceuticals North America Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-13

Filing date

2008-11-12

Publication date

2012-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40170671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE537829(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-11-12 Application filed by Lundbeck & Co As H, Takeda Pharmaceuticals North America Inc filed Critical Lundbeck & Co As H

2012-01-15 Application granted granted Critical

2012-01-15 Publication of ATE537829T1 publication Critical patent/ATE537829T1/de

Links

102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 title 1
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
230000000694 effects Effects 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Anesthesiology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Gynecology & Obstetrics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Nutrition Science (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT08850935T 2007-11-13 2008-11-12 Therapeutische verwendung von verbindungen mit kombinierter sert-, 5-ht3 und 5-ht1a-aktivität ATE537829T1 (de)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US98771007P	2007-11-13	2007-11-13
DKPA200701607		2007-11-13
US1372207P	2007-12-14	2007-12-14
DKPA200701788		2007-12-14
US9784008P	2008-09-17	2008-09-17
DKPA200801300		2008-09-17
PCT/DK2008/050271 WO2009062517A1 (en)	2007-11-13	2008-11-12	Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity

Publications (1)

Publication Number	Publication Date
ATE537829T1 true ATE537829T1 (de)	2012-01-15

Family

ID=40170671

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT08850935T ATE537829T1 (de)	2007-11-13	2008-11-12	Therapeutische verwendung von verbindungen mit kombinierter sert-, 5-ht3 und 5-ht1a-aktivität

Country Status (30)

Country	Link
US (5)	US9278096B2 (de)
EP (3)	EP2219647B2 (de)
JP (2)	JP5603244B2 (de)
KR (1)	KR101536023B1 (de)
CN (1)	CN102014908A (de)
AR (1)	AR069260A1 (de)
AT (1)	ATE537829T1 (de)
AU (1)	AU2008323390B2 (de)
BR (1)	BRPI0820474B8 (de)
CA (1)	CA2705163C (de)
CL (1)	CL2008003363A1 (de)
CO (1)	CO6270322A2 (de)
CY (2)	CY1112646T1 (de)
DK (2)	DK2219647T4 (de)
EA (1)	EA027783B1 (de)
ES (2)	ES2379419T5 (de)
HR (2)	HRP20120144T4 (de)
HU (1)	HUE029588T2 (de)
IL (1)	IL205466A (de)
LT (1)	LT2431039T (de)
MX (1)	MX2010004688A (de)
NZ (1)	NZ585247A (de)
PL (2)	PL2219647T3 (de)
PT (2)	PT2219647E (de)
RS (2)	RS52256B2 (de)
SG (1)	SG10201405001XA (de)
SI (2)	SI2219647T2 (de)
TW (1)	TW200932233A (de)
WO (1)	WO2009062517A1 (de)
ZA (1)	ZA201003350B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200932233A (en) *	2007-11-13	2009-08-01	Lundbeck & Co As H	Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
JP2013502446A (ja)	2009-08-24	2013-01-24	ハー・ルンドベック・アクチエゼルスカベット	１−［２−（２，４−ジメチル−フェニルスルファニル）−フェニル］ピペラジンの新規組成物
TW201212918A (en)	2010-08-23	2012-04-01	Lundbeck & Co As H	Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
JP6348283B2 (ja) *	2011-01-27	2018-06-27	ニューレンファーマシューティカルズリミテッド	グリシル−ｌ−２−メチルプロリル−ｌ−グルタミン酸を用いる自閉症スペクトラム障害の治療
JP6078466B2 (ja)	2011-07-21	2017-02-08	学校法人名城大学	セロトニントランスポーター分析キット及び血中ユビキチン化セロトニントランスポーター分析キット
CN104853755B (zh)	2012-12-13	2017-08-22	H.隆德贝克有限公司	包含沃替西汀和多奈哌齐的组合物
JP6323979B2 (ja) *	2013-01-17	2018-05-16	学校法人名城大学	うつ病マーカー、アッセイ方法、測定方法、うつ病薬のスクリーニング方法及びキット
WO2014191548A1 (en) *	2013-05-31	2014-12-04	Lek Pharmaceuticals D.D.	New process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine
EP2878596A1 (de) *	2013-11-29	2015-06-03	LEK Pharmaceuticals d.d.	Synthese von Vortioxetin über (2-(Piperazin-1-yl)phenyl)lithium-Zwischenprodukte
JP6448645B2 (ja) *	2013-12-20	2019-01-09	ハー・ルンドベック・アクチエゼルスカベット	メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用
CN103788019B (zh) *	2014-01-22	2015-10-07	苏州明锐医药科技有限公司	沃替西汀的制备方法
EA029060B1 (ru)	2014-01-31	2018-02-28	Эгиш Дьёдьсердьяр Зрт.	Способ получения солей вортиоксетина
EP2930171A1 (de) *	2014-04-07	2015-10-14	LEK Pharmaceuticals d.d.	Synthese von Vortioxetin über (2,4-Dimethylphenyl) (2-Iodophenyl)sulfan-Zwischenprodukt
CN104119299B (zh) *	2014-08-13	2016-08-17	北京蓝贝望生物医药科技股份有限公司	沃赛汀或沃替西汀的氢溴酸盐
CN104119298B (zh) *	2014-08-13	2016-08-24	北京蓝贝望生物医药科技股份有限公司	氢溴酸沃赛汀或氢溴酸沃替西汀
CN104610195B (zh) *	2015-01-30	2017-06-27	上虞京新药业有限公司	沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
JO3456B1 (ar) *	2015-05-13	2020-07-05	H Lundbeck As	فيروتيوكسيتين بيروجلوتامات
EP3324952B1 (de) *	2015-07-17	2020-12-16	Institut Pasteur	5-hydroxytryptamin-1b-rezeptor-stimulierendes mittel zur verwendung als promoter von satellitenzellenselbsterneuerung und/oder -differenzierung
JP2019524682A (ja)	2016-07-01	2019-09-05	ハー・ルンドベック・アクチエゼルスカベット	抗うつ作用の速い発現のためのボルチオキセチン投与計画
EP3870292A4 (de)	2018-10-26	2022-11-09	The Research Foundation for The State University of New York	Kombination von serotonin-spezifischem wiederaufnahmeinhibitor und serotonin-1a-rezeptor-partialagonist zur verminderung von l-dopa-induzierter dyskinesie
KR20220163997A (ko)	2020-04-03	2022-12-12	하. 룬드벡 아크티에셀스카브	정서적 둔마의 예방 또는 치료를 위한 1-[2-(2,4-디메틸페닐설파닐)-페닐]피페라진
WO2023036820A1 (en)	2021-09-10	2023-03-16	H. Lundbeck A/S	Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
KR20230148676A (ko)	2022-04-18	2023-10-25	영진약품 주식회사	라베프라졸 및 탄산수소나트륨을 포함하는 조성물 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
YU163075A (en) *	1975-07-21	1982-05-31	Science Union & Cie	Process for preparing new phenoxy derivatives
US5258387A (en) *	1990-08-21	1993-11-02	Hoffmann-La Roche Inc.	Tricyclic pyridone derivatives
UA81749C2 (uk) *	2001-10-04	2008-02-11	Х. Луннбек А/С	Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
MXPA04005989A (es) *	2001-12-20	2004-09-27	Lundbeck & Co As H	Derivados de ariloxifenilo y arilsulfanilfenilo.
HRP20080478T3 (hr)	2003-04-04	2009-02-28	H. Lundbeck A/S	Derivati 4-(2-fenilsulfanil-fenil)-piperidina kaoinhibitori ponovne pohrane serotonina
US20060019938A1 (en)	2003-12-31	2006-01-26	Beer Tomasz M	Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
KR20090028712A (ko) *	2006-06-16	2009-03-19	하. 룬트벡 아크티에 셀스카브	인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ｈｔ3 및 5-ｈｔ1ａ 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진
TW200848411A (en) *	2007-03-20	2008-12-16	Lundbeck & Co As H	Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en)	2007-11-13	2009-08-01	Lundbeck & Co As H	Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
JP2013502446A (ja)	2009-08-24	2013-01-24	ハー・ルンドベック・アクチエゼルスカベット	１−［２−（２，４−ジメチル−フェニルスルファニル）−フェニル］ピペラジンの新規組成物

2008
- 2008-11-03 TW TW097142306A patent/TW200932233A/zh unknown
- 2008-11-11 AR ARP080104919A patent/AR069260A1/es unknown
- 2008-11-12 HU HUE11193237A patent/HUE029588T2/en unknown
- 2008-11-12 PT PT08850935T patent/PT2219647E/pt unknown
- 2008-11-12 HR HRP20120144TT patent/HRP20120144T4/hr unknown
- 2008-11-12 DK DK08850935.1T patent/DK2219647T4/da active
- 2008-11-12 EP EP08850935.1A patent/EP2219647B2/de active Active
- 2008-11-12 WO PCT/DK2008/050271 patent/WO2009062517A1/en not_active Ceased
- 2008-11-12 KR KR1020107010492A patent/KR101536023B1/ko not_active Ceased
- 2008-11-12 AU AU2008323390A patent/AU2008323390B2/en active Active
- 2008-11-12 BR BRPI0820474A patent/BRPI0820474B8/pt active IP Right Grant
- 2008-11-12 ES ES08850935T patent/ES2379419T5/es active Active
- 2008-11-12 CL CL2008003363A patent/CL2008003363A1/es unknown
- 2008-11-12 RS RS20120087A patent/RS52256B2/sr unknown
- 2008-11-12 PL PL08850935T patent/PL2219647T3/pl unknown
- 2008-11-12 RS RS20160756A patent/RS55147B1/sr unknown
- 2008-11-12 CA CA2705163A patent/CA2705163C/en active Active
- 2008-11-12 US US12/741,780 patent/US9278096B2/en active Active
- 2008-11-12 LT LTEP11193237.2T patent/LT2431039T/lt unknown
- 2008-11-12 EA EA201070598A patent/EA027783B1/ru not_active IP Right Cessation
- 2008-11-12 CN CN2008801164637A patent/CN102014908A/zh active Pending
- 2008-11-12 AT AT08850935T patent/ATE537829T1/de active
- 2008-11-12 DK DK11193237.2T patent/DK2431039T3/en active
- 2008-11-12 SI SI200830548T patent/SI2219647T2/sl unknown
- 2008-11-12 PT PT111932372T patent/PT2431039T/pt unknown
- 2008-11-12 SI SI200831677A patent/SI2431039T1/sl unknown
- 2008-11-12 EP EP11193237.2A patent/EP2431039B1/de active Active
- 2008-11-12 ES ES11193237.2T patent/ES2591110T3/es active Active
- 2008-11-12 NZ NZ585247A patent/NZ585247A/en not_active IP Right Cessation
- 2008-11-12 SG SG10201405001XA patent/SG10201405001XA/en unknown
- 2008-11-12 EP EP16178423.6A patent/EP3115050A1/de not_active Withdrawn
- 2008-11-12 MX MX2010004688A patent/MX2010004688A/es active IP Right Grant
- 2008-11-12 PL PL11193237.2T patent/PL2431039T3/pl unknown
- 2008-11-12 JP JP2010533436A patent/JP5603244B2/ja active Active
2010
- 2010-04-29 IL IL205466A patent/IL205466A/en active IP Right Grant
- 2010-05-12 ZA ZA2010/03350A patent/ZA201003350B/en unknown
- 2010-05-13 CO CO10057476A patent/CO6270322A2/es not_active Application Discontinuation
2012
- 2012-02-24 CY CY20121100199T patent/CY1112646T1/el unknown
2014
- 2014-05-14 JP JP2014100815A patent/JP5841636B2/ja active Active
2016
- 2016-02-12 US US15/043,167 patent/US9744166B2/en active Active
- 2016-09-01 HR HRP20161121TT patent/HRP20161121T1/hr unknown
- 2016-09-07 CY CY20161100885T patent/CY1117978T1/el unknown
2017
- 2017-07-27 US US15/661,392 patent/US20180161321A1/en not_active Abandoned
2020
- 2020-05-12 US US15/930,014 patent/US11628166B2/en active Active
2023
- 2023-04-04 US US18/130,749 patent/US20240082239A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2219647A1 (de)	2010-08-25
ES2591110T3 (es)	2016-11-24
ZA201003350B (en)	2011-08-31
US9744166B2 (en)	2017-08-29
JP2014193891A (ja)	2014-10-09
EP2219647B2 (de)	2020-07-29
RS52256B2 (sr)	2020-11-30
US20240082239A1 (en)	2024-03-14
RS55147B1 (sr)	2016-12-30
US9278096B2 (en)	2016-03-08
DK2219647T3 (da)	2012-03-19
LT2431039T (lt)	2016-10-10
EP2431039A1 (de)	2012-03-21
CY1112646T1 (el)	2016-02-10
EP2219647B1 (de)	2011-12-21
BRPI0820474B1 (pt)	2020-08-04
CA2705163A1 (en)	2009-05-22
US11628166B2 (en)	2023-04-18
CL2008003363A1 (es)	2009-06-05
PT2431039T (pt)	2016-09-29
RS52256B (sr)	2012-10-31
MX2010004688A (es)	2010-09-09
EA201070598A1 (ru)	2010-10-29
HRP20120144T1 (en)	2012-04-30
US20210093631A1 (en)	2021-04-01
JP2011503125A (ja)	2011-01-27
HRP20161121T1 (hr)	2017-01-27
AR069260A1 (es)	2010-01-06
AU2008323390A1 (en)	2009-05-22
EA027783B1 (ru)	2017-09-29
SI2219647T1 (sl)	2012-06-29
KR101536023B1 (ko)	2015-07-10
BRPI0820474A2 (pt)	2017-05-23
IL205466A0 (en)	2010-12-30
KR20100099115A (ko)	2010-09-10
EP3115050A1 (de)	2017-01-11
WO2009062517A1 (en)	2009-05-22
PT2219647E (pt)	2012-03-16
ES2379419T3 (es)	2012-04-25
JP5841636B2 (ja)	2016-01-13
SG10201405001XA (en)	2014-10-30
CY1117978T1 (el)	2017-05-17
US20110201617A1 (en)	2011-08-18
EP2431039B1 (de)	2016-07-20
IL205466A (en)	2014-06-30
ES2379419T5 (es)	2021-05-04
KR101536023B9 (ko)	2023-03-29
CA2705163C (en)	2013-02-12
US20160228430A1 (en)	2016-08-11
SI2431039T1 (sl)	2017-01-31
PL2219647T3 (pl)	2012-07-31
US20180161321A1 (en)	2018-06-14
PL2431039T3 (pl)	2016-12-30
DK2219647T4 (da)	2020-09-28
TW200932233A (en)	2009-08-01
JP5603244B2 (ja)	2014-10-08
AU2008323390B2 (en)	2013-10-24
DK2431039T3 (en)	2016-09-26
NZ585247A (en)	2012-03-30
BRPI0820474B8 (pt)	2021-05-25
HUE029588T2 (en)	2017-03-28
CN102014908A (zh)	2011-04-13
SI2219647T2 (sl)	2020-11-30
HRP20120144T4 (hr)	2020-11-13
CO6270322A2 (es)	2011-04-20

Publication	Publication Date	Title
ATE537829T1 (de)	2012-01-15	Therapeutische verwendung von verbindungen mit kombinierter sert-, 5-ht3 und 5-ht1a-aktivität
FIC20240036I1 (fi)	2024-10-29	Geeniterapia, joka ilmentää ihmisen hyytymistekijä IX:n muunnosta R338L
NO343929B3 (no)	2019-07-08	1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte
ATE531696T1 (de)	2011-11-15	Harnstoff-derivate von benzomorphanen, entsprechende gerüste, medikamente mit solchen verbindungen und ihre verwendung
EP2427195A4 (de)	2015-04-01	Heterocyclische verbindungen und ihre verwendung
DK2245199T3 (da)	2014-02-03	Anvendelse af mikrovesikler i diagnosticering, prognosticering og behandling af medicinske sygdomme og tilstande
EP2373163A4 (de)	2012-10-24	Heterocyclische verbindungen und anwendungsverfahren
EP3592081C0 (de)	2024-01-31	Ausrichtung von semi-persistierender zeitplanung und diskontinuierlichem empfang
BRPI1012129A2 (pt)	2016-03-29	enantiômeros de compostos spiro-oxindol e sua utilização como agentes terapêuticos.
DE112007000789A5 (de)	2009-01-02	Verwendung von Bora-tetraazepentalenen
NO345064B1 (no)	2020-09-14	Anvendelse av kombinasjonslegemidler, omfattende antimykotika
HUE045367T2 (hu)	2019-12-30	Kombinált terápia diabétesz kezelésére
DE602008001981D1 (de)	2010-09-09	Stellung und therapeutische verwendung
EP2287155A4 (de)	2012-05-09	Acylthioharnstoffverbindung und salze davon, und die verwendung der verbindung bzw. der salze
PL2238119T3 (pl)	2016-05-31	Chinazoliny i pokrewne związki heterocykliczne i ich zastosowanie terapeutyczne
ATE512970T1 (de)	2011-07-15	Dimere von artemisininderivaten, deren herstellung und deren therapeutische verwendung
JO3715B1 (ar)	2021-01-31	منشط مستقبل اسيتيل كولين الفا-7 النيكوتيني
SMT201600156B (it)	2016-08-31	Trattamento dell’osteoartrite
ATE540023T1 (de)	2012-01-15	Neuartige 3-aminoalkyl-1,3-dihydro-2h-indol-2-on- derivate, ihre herstellung und therapeutische verwendung
BRPI0818121A2 (pt)	2015-11-17	diespiro 1,2,4-trioxolano e seus métodos de fabricação e utilização
EP2416776A4 (de)	2012-09-26	Verwendung von tetrahydrobiopterin als marker und therapeutikum für morbus fabry
DE602006000349D1 (de)	2008-02-07	Medizinisches Instrument mit medizinischer Behandlungselektrode
DK1940409T3 (da)	2010-11-29	Nye lægemiddelkombinationer til behandling af åndedrætssygdomme
PL2330892T3 (pl)	2017-05-31	Sposoby leczenia z zastosowaniem leków wychwytujących amoniak
DK1856070T3 (da)	2011-09-26	Nye lægemidler til behandling af luftvejssygdomme